Melanotan 2 Results: Tanning Timeline, Before & After & Realistic Expectations

Overview

Melanotan II (MT-2) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide that binds melanocortin receptors and drives melanin production in skin cells (melanocytes). Originally developed at the University of Arizona in the early 1990s as a potential sunless tanning agent and later investigated for sexual dysfunction, Melanotan 2 became widely used in the research and bodybuilding communities for its tanning and libido-enhancing effects. This article examines what results Melanotan 2 actually produces — the tanning timeline, how skin type affects outcomes, systemic effects beyond tanning, realistic before-and-after expectations, and what fading looks like after discontinuation.

Tanning Timeline: When Does Melanotan 2 Start Working?

The tanning response to Melanotan 2 is not instantaneous — it requires both sufficient peptide loading and UV exposure to produce visible results. The typical timeline unfolds as follows:

• Days 1–3 (Loading begins, no visible change): Initial doses (typically 0.25–0.5 mg subcutaneous) begin activating melanocortin 1 receptors (MC1R) on melanocytes, stimulating increased melanin synthesis. No visible color change is expected at this stage. Side effects (nausea, facial flushing, spontaneous erections in men) are most prominent in the first few days as the body adjusts.
• Days 3–7 (Melanocyte priming with UV exposure): With UV exposure — even brief sessions of 10–15 minutes — melanin deposition begins. Some lighter-skinned users report first visible color at the end of the first week, though this depends heavily on baseline skin type and UV exposure frequency.
• Weeks 1–2 (First visible results with regular UV): The 1–2 week window is typically when first significant, noticeable tanning appears with consistent UV exposure. Those with naturally olive or tanned skin (Fitzpatrick type III–IV) may see results at the earlier end; very fair skin (type I–II) may need longer to develop visible color, but MT-2 can help them tan in ranges previously difficult.
• Weeks 2–4 (Progressive deepening): With continued loading doses and regular UV exposure, the tan deepens progressively. The combination of increased melanin production and UV-stimulated melanin distribution produces a natural-looking tan rather than artificial orange discoloration (as with DHA-based tanning products).
• Weeks 4–8 (Saturation phase): Many users describe a "saturation" point where further deepening becomes marginal. Once this level is reached, the user transitions to a maintenance dose (typically 0.5–1 mg 1–2x/week) to sustain the tan with or without ongoing UV exposure.
• Beyond saturation (UV-independent maintenance): One of the distinguishing features of Melanotan 2 that community users report is that once a deep tan is achieved, it can be maintained with low maintenance doses and minimal UV exposure — though some UV is still recommended for best results.

How Skin Type Affects Melanotan 2 Results (Fitzpatrick Scale)

Results from Melanotan 2 are highly dependent on baseline skin type. The Fitzpatrick phototype scale classifies skin from type I (very fair, always burns) to type VI (deeply pigmented, never burns), and this classification strongly predicts both the timeline and degree of tanning achievable with MT-2:

• Fitzpatrick Type I (Very fair, freckled, always burns): These individuals have the fewest melanocytes and lowest baseline melanin production. MT-2 can enable tanning that would be essentially impossible without the peptide, but results take longer (often 3–4+ weeks of loading) and maximum achievable tan is lighter than in higher phototypes. The value proposition for Type I is enabling some tanning rather than burning.
• Fitzpatrick Type II (Fair, burns easily, sometimes tans): Results are achievable but slower. 2–3 weeks of loading with regular UV typically produces visible color. Community reports consistently describe this group as needing careful, gradual UV exposure to avoid burns during the loading phase.
• Fitzpatrick Type III (Medium, sometimes burns, always tans): The "sweet spot" for MT-2 results — visible color often within 1–2 weeks, with deep tanning achievable within 4–6 weeks of consistent use. This group tends to report the most reliable and pronounced results.
• Fitzpatrick Type IV (Olive/Mediterranean, rarely burns, always tans): Often already able to tan well, this group uses MT-2 primarily for darker, faster tanning with less UV exposure. Results are rapid, with visible deepening often within days of starting and UV exposure.
• Fitzpatrick Types V–VI (Brown to deeply pigmented): These individuals already have high baseline melanin. Melanotan 2 still activates MC1R receptors, but visible tanning effect is minimal — the baseline skin is already deeply pigmented. This group represents the least common MT-2 users for tanning purposes.
• Mole response: Across all skin types, Melanotan 2 typically darkens existing moles and nevi, sometimes significantly. This is not a sign of malignancy, but existing moles should be monitored by a dermatologist during use, as the pigmentation change can obscure early changes.

Saturation Dosing vs. Maintenance: The Two-Phase Approach

Community experience and early research protocols suggest Melanotan 2 use follows a two-phase structure that affects results:

• Loading/saturation phase: Most protocols begin with daily or near-daily subcutaneous injections of 0.25–0.5 mg, gradually increasing to 0.5–1 mg as tolerance to side effects develops. The goal is to saturate melanocortin receptors and maximize melanin production while building UV exposure carefully.
• Transition to maintenance: After achieving the desired skin tone (typically 4–8 weeks for most users), the dose is reduced to once or twice weekly at approximately 0.5–1 mg. This maintains the tan with significantly less peptide.
• Effect of UV exposure during loading: UV exposure is critical for optimal results. MT-2 stimulates melanin synthesis, but melanin distribution and fixation in skin cells is enhanced by UV. Most protocols recommend 10–20 minute UV sessions (natural sunlight or tanning bed) during loading for best color depth.
• Side effect burden during saturation: Nausea, facial flushing, spontaneous erections (in men), yawning, and appetite suppression are most prominent during the loading phase and typically diminish as the body adjusts or as the dose is stabilized.
• Protocol duration considerations: Community reports suggest the color built during a saturation phase is more durable than color from a short course — users who complete 6–8 weeks of loading maintain their tan more easily with maintenance doses.

Beyond Tanning: Libido, Appetite, and Other Effects as "Results"

Melanotan 2 is a non-selective melanocortin agonist, binding not only MC1R (tanning) but also MC3R and MC4R, which are expressed centrally and regulate appetite and sexual function. These effects are significant components of the overall results profile:

• Libido enhancement and spontaneous erections: MC4R activation in the hypothalamus mediates sexual arousal. MT-2 frequently produces increased libido and spontaneous erections in men, effects that were noted in early human clinical trials. This was the basis for PT-141 (bremelanotide), a more MC4R-selective analogue developed specifically for sexual dysfunction. Community reports consistently describe this as one of the more noticeable early effects, often appearing before significant tanning.
• Appetite suppression: MC4R and MC3R activation suppresses appetite through central mechanisms. Users commonly report reduced hunger and, for some, meaningful weight loss during MT-2 loading phases. This is considered a side effect by tanning-focused users and a secondary benefit by others.
• Yawning and lethargy: Early after injection, central melanocortin activation frequently produces yawning and mild sedation — a characteristic "MT-2 yawn" that is widely reported in community discussions and was documented in clinical research. This typically occurs 30–90 minutes post-injection.
• Mood changes: Some users report mild mood elevation or increased wellbeing, potentially related to central MC receptor activity. A smaller subset reports anxiety or mood instability — these are likely individual variations in central melanocortin sensitivity.
• Facial flushing: Vasodilation following MT-2 injection is common in the first few days to weeks. This typically diminishes with dose stabilization.
• These systemic effects are important to understand because they occur regardless of skin type or tanning goal. Users primarily seeking tanning results should expect to experience these additional effects, at least during the loading phase.

Before and After: Realistic Expectations

Melanotan 2 produces genuine, measurable tanning results — but with important nuances that affect realistic before-and-after expectations:

• Color quality vs. artificial tanning: Unlike DHA-based (dihydroxyacetone) topical tanners that produce an orange-brown surface stain, MT-2 increases actual melanin production, resulting in a color that community reports consistently describe as more natural-looking. The tan tends to be even across the body, including areas not directly exposed to UV.
• Baseline limits results: What's achievable is bounded by skin type. A Fitzpatrick Type I person using MT-2 may achieve a light-to-medium tan — real improvement over their baseline, but not the same deep tan a Type III–IV person achieves. Setting expectations based on skin type is essential for avoiding disappointment.
• Timeline to visible before-and-after results: Most users with adequate skin type achieve noticeable color by weeks 2–3; the most dramatic transformations typically require 6–10 weeks of consistent loading and UV exposure.
• Mole darkening in before-and-after: This is a universally reported component of before-and-after results — existing moles and freckles darken, sometimes dramatically. This should be monitored but is typically benign pigmentation change rather than pathological transformation.
• Results under the Fitzpatrick scale for the community: Type I–II users report the most transformative relative results (going from no ability to tan to moderate tan); Type III–IV users report deepest absolute color.
• No result without UV: Users who attempt to use MT-2 without any UV exposure consistently report significantly inferior tanning results, though some melanin synthesis still occurs. UV remains a meaningful amplifier of outcome.

Fading Timeline: How Long Do Results Last After Stopping?

One of the practical questions for Melanotan 2 use is how long results persist after discontinuation:

• Onset of fading: Most community reports describe the tan beginning to fade within 1–3 weeks of stopping MT-2 completely, particularly if UV exposure also decreases. The tan does not disappear overnight — it fades gradually as melanocytes return to baseline activity and existing melanin is shed through normal skin turnover.
• Rate of fading: The natural skin cell cycle (keratinocyte turnover) takes approximately 28–40 days in adults. As new, less-pigmented cells replace the melanin-loaded cells produced during MT-2 use, visible fading accelerates. Full return to baseline typically occurs over 4–8 weeks depending on how deep the tan was.
• Maintenance dose can preserve results: At low maintenance doses (0.5–1 mg 1–2x/week with occasional UV), many users report sustaining their tan for extended periods without complete loss. This is the "semi-permanent tan" effect commonly described in community discussions.
• Reloading faster the second time: Users who have previously saturated with MT-2 often report faster results when starting a new cycle, possibly because the melanocyte population has been previously activated and some residual melanin persists in deeper skin layers.
• Seasonal considerations: Faster fading occurs in winter (less UV) for those at higher latitudes, with the reverse in summer months. This is consistent with normal melanin physiology and is not specific to MT-2.

References

1. Bremelanotide: An Overview of Preclinical CNS Effects on Female Sexual Function (2003) — PubMed
2. Melanotan II: A Melanocortin Agonist With Diverse Pharmacological Activities (1998) — PubMed
3. Alpha-Melanocyte Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases (2013) — PubMed
4. Human sexual response in the laboratory and its relationship to Melanotan II (2000) — PubMed